{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-25-000030","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.315561+00:00","generated_at":"2026-05-23T00:42:13.189565+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Shattuck Labs Q1 net loss $13.7M, cash $60.9M; SL-325 IND filing expected Q3 2025","bullets":["Net loss of $13.7M ($0.27 per share) for Q1 2025 compared to $18.5M ($0.37 per share) in Q1 2024.","Cash and equivalents of $60.9M as of Mar 31, 2025, expected to fund operations into 2027.","SL-325 IND filing expected in Q3 2025; Phase 1 SAD portion first patient in Q3 2025, enrollment complete Q2 2026.","R&D expenses decreased to $9.9M from $16.3M YoY; G&A expenses decreased to $4.5M from $4.9M.","Wind-down activities for discontinued oncology programs substantially completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-25-000030","json":"https://secwatch.observer/filing/0001680367-25-000030.json","markdown":"https://secwatch.observer/filing/0001680367-25-000030.md","text":"https://secwatch.observer/filing/0001680367-25-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036725000030/0001680367-25-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036725000030/sttk-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:42:13.189565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}